

AMARIN CORP PLC\UK
Form 8-K
June 19, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 19, 2013

Amarin Corporation plc

(Exact name of registrant as specified in its charter)

England and Wales
(State or other jurisdiction

of incorporation)

000-21392
(Commission

File Number)

Not applicable
(I.R.S. Employer
Identification No.)

Edgar Filing: AMARIN CORP PLC\UK - Form 8-K

**2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2,
Ireland**

(Address of principal executive offices)

Not applicable

(Zip Code)

Registrant's telephone number, including area code: +353 1 6699 020

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On June 19, 2013, Amarin Corporation plc ("Amarin") issued a press release titled "Amarin Informed by FDA of October 4th Advisory Committee Decision in Connection with Supplemental New Drug Application (sNDA) for Vascepa^(R) in the Treatment of Patients with High Triglycerides (≥ 200 mg/dL and < 500 mg/dL) with Mixed Dyslipidemia. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description
99.1	Press Release, dated June 19, 2013

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 19, 2013

Amarin Corporation plc

By: /s/ John Thero
John Thero
President

Exhibit Index

Exhibit

No.	Description
99.1	Press Release, dated June 19, 2013